DB16651InvestigationalProtein Based Therapies
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
- Mechanism
- Curator reviewed
Pharmacologically active on Cytotoxic T-lymphocyte protein 4
- Code names
- AGEN-1181
Resolves to
Compound
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with Botensilimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account